Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

Inclusion Criteria: * Fulfils at least 4 of the 11 American College of Rheumatology (ACR) classification criteria for SLE. * Weight greater than or equal to 40.0 kg. * Diagnosis of pediatric or adult SLE with chronic disease activity requiring ongoing treatment or observation for ≥ 24 weeks prior to screening. * Currently receiving stable dose of oral prednisone and/or antimalarials/immunosuppressives. * Active moderate to severe SLE disease based on SLE disease activity score. Exclusion Criteria: * Active severe or unstable neuropsychiatric SLE. * Active severe SLE-driven renal disease or unstable renal disease. * Clinically significant active infection including ongoing and chronic infections. * Known history of a primary immunodeficiency or an underlying condition such as human immunodeficiency virus infection or splenectomy that predisposes the subject to infection. * Confirmed positive tests for hepatitis B or positive test for hepatitis C.